EdiLabs Recognised as a Top VC Opportunity at PurposeTech Demo Day

EdiLabs was honoured to be selected from over 140 startups to pitch at the PurposeTech Demo Day, the finale of the Startup Funding Bootcamp on 10th September 2025. Out of this highly competitive cohort, just six companies were chosen to present to a panel of 23 investors, and EdiLabs was one of them.

This recognition highlights EdiLabs as one of the most exciting VC opportunities in health right now. While the other five finalists were all AI-driven startups, EdiLabs stood out as the sole life sciences company, representing a very different but equally high-potential pathway for venture-scale returns.

Our strength lies in our team and partners. Behind EdiLabs is a committed team of leading scientists and R&D specialists in drug development, preclinical trials, and IP protection, with development supported by PlantForm Corporation (Canada) and preclinical testing by Charles River Laboratories (Finland). Together, we are pioneering the first platform for edible biologics. By turning injectable drugs into safe, scalable oral therapies, our platform has the potential to transform access to life-changing treatments across multiple high-value therapeutic areas.

We are grateful to the PurposeTech team, mentors, and jury of investors for their support, and look forward to advancing conversations with VCs as we move towards our next funding milestone.

📌 Read more on PurposeTech’s announcement: PurposeTech Demo Day Wrap-Up.